Esperion Therapeutics (NASDAQ:ESPR) Price Target Cut to $4.00 by Analysts at Needham & Company LLC
Esperion Therapeutics (NASDAQ:ESPR – Free Report) had its target price lowered by Needham & Company LLC from $5.00 to $4.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other brokerages have also issued reports on ESPR. HC Wainwright reaffirmed […]
Esperion Therapeutics (NASDAQ:ESPR – Free Report) had its target price lowered by Needham & Company LLC from $5.00 to $4.00 in a research report released on Wednesday morning,Benzinga reports. The brokerage currently has a buy rating on the biopharmaceutical company’s stock. A number of other brokerages have also issued reports on ESPR. HC Wainwright reaffirmed […]
